Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;73(12):1257-65.
doi: 10.1007/s40265-013-0091-6.

Relapsed triple-negative breast cancer: challenges and treatment strategies

Valentina Guarneri  1 , Maria Vittoria Dieci, Pierfranco Conte
Affiliations
Review

Relapsed triple-negative breast cancer: challenges and treatment strategies

Valentina Guarneri et al. Drugs. 2013 Aug.

Abstract

Triple negative breast cancer (TNBC) is the most lethal form of breast cancer. Treatment options for advanced disease are limited, with a median survival from the time of developing metastases rarely exceeding 1 year. TNBC is heterogeneous, and harbours several molecular alterations. Unfortunately, up to now, clinical trials combining targeted agents and chemotherapy have failed to show substantial survival improvement; therefore, chemotherapy remains the backbone of treatment. No major advances have been made in the field of cytotoxic treatments, and hopefully ongoing trials will contribute to a more precise definition of the role of platinum salts in sporadic and BRCA-mutated TNBC. Moreover, recent gene expression data suggest that TNBC can be further segmented into smaller subgroups, characterized by different activated pathways, which may therefore warrant different targeted treatments. The lack of efficacy that has been observed for the majority of targeted agents in TNBC so far may derive from the inclusion of unselected TNBC patient populations, not enriched for patients presenting an alteration in the target. Therefore, one of the major challenges in the future is to integrate biological data into clinical trials to obtain the highest efficacy from promising targeted treatments such as anti-angiogenetic agents, poly (ADP-ribose) polymerase-1 (PARP), epidermal growth factor receptor, fibroblast growth factor receptor, androgen receptor and phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitors.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Biochem J. 2005 Feb 15;386(Pt 1):119-25 - PubMed
    1. J Clin Oncol. 2010 Jul 10;28(20):3256-63 - PubMed
    1. Clin Cancer Res. 2011 Nov 1;17(21):6905-13 - PubMed
    1. N Engl J Med. 2007 Dec 27;357(26):2666-76 - PubMed
    1. Oncologist. 2011;16 Suppl 1:61-70 - PubMed

MeSH terms

Substances

LinkOut - more resources